Oct 6 (Reuters) - Eli Lilly (LLY.N), opens new tab will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Riding high on the success of its blockbuster weight loss drug, Eli ...

Of the title character in “Lost Evangeline,” it is said she “lived a great life of the imagination.” You could say the same about Evangeline’s creator, Kate DiCamillo. The beloved, Minneapolis-based ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose. Lilly closed the trial on ...

Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a single patient, citing “strategic business reasons.” The study was designed to test bimagrumab, an asset Lilly acquired in ...

EVANGELINE PARISH — Construction crews have spent more than a year working nonstop—pouring concrete, raising steel beams, and bringing the new Evangeline Parish jail closer to reality. Now, officials ...

Indianapolis-based pharmaceutical giant Eli Lilly confirms plans to build a $5 billion manufacturing facility just west of Richmond, Virginia. (Courtesy Eli Lilly) Indianapolis-based pharmaceutical ...

Eli Lilly on Tuesday announced a $5 billion investment in a manufacturing facility in Virginia as the pharmaceutical giant looks to expand its domestic production capacity amid the threat of tariffs.

Eli Lilly & Co.’s obesity pill prompted enough weight loss in a large clinical trial to be meaningful for patients and have far-reaching implications for the field, doctors said. The US drugmaker’s ...

Sept 9 (Reuters) - Drugmaker Eli Lilly (LLY.N), opens new tab said on Tuesday it is launching an artificial intelligence and machine learning platform that provides biotech companies access to drug ...

As the oral GLP-1 race intensifies, Eli Lilly has slimmed back the number of phase 2 trials it is conducting for one of its contenders. The Big Pharma had been running three midstage studies of the ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...